Cartesian Therapeutics (NASDAQ: RNAC) net income
Cartesian Therapeutics reported a net loss of $130.3m for fiscal 2025; in fiscal 2024 it reported a net loss of $77.4m. Earnings per share were −$5.02.
Cartesian Therapeutics's best year of the last 10 was fiscal 2022. It reported a loss in 9 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$130.3m | — | −4,658.6% | −$5.02 |
| 2024 | −$77.4m | — | −199.0% | −$4.48 |
| 2023 | −$219.7m | −721.0% | −844.9% | −$1.66 |
| 2022 | $35.4m | — | 31.9% | $0.24 |
| 2021 | −$25.7m | — | −30.2% | −$0.22 |
| 2020 | −$68.9m | — | −415.0% | −$0.68 |
| 2019 | −$55.4m | — | −829.0% | −$1.22 |
| 2018 | −$65.3m | — | −7,235.4% | — |
| 2017 | −$65.3m | — | −31,556.0% | — |
| 2016 | −$36.2m | — | −448.0% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Cartesian Therapeutics net income compared with its sector
By net income for its latest fiscal year, Cartesian Therapeutics ranks 364th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Cartesian Therapeutics, −4,658.6%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 362nd | ORIC Pharmaceuticals | −$129.5m | — |
| 363rd | Protagonist Therapeutics | −$130.1m | −282.8% |
| 364th | Cartesian Therapeutics | −$130.3m | −4,658.6% |
| 365th | Maravai LifeSciences | −$130.8m | −70.4% |
| 366th | Kestra Medical Technologies | −$131.6m | −138.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Cartesian Therapeutics
- How much did Cartesian Therapeutics earn in fiscal 2025?
- Cartesian Therapeutics reported a net loss of $130.3m for fiscal 2025. In fiscal 2024 it reported a net loss of $77.4m.
- What are the earnings per share of Cartesian Therapeutics?
- They were −$5.02 in fiscal 2025, compared with −$4.48 in fiscal 2024.
- What was the most profitable year for Cartesian Therapeutics?
- Of its last 10 fiscal years, fiscal 2022, with $35.4m.
- Where does Cartesian Therapeutics rank in its sector by net income?
- It ranks 364th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Cartesian Therapeutics come from?
- From the annual report (Form 10-K) that Cartesian Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Cartesian Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Cartesian Therapeutics: the Cartesian Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.